Pfizer Teams Up With Biocon In Bid to Dominate Global Biosimilar Insulin Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer tells analysts the deal will have an incremental not "instrumental" impact on its established products and emerging markets strategy.